Objectives: Although high-dose rifampicin holds promise for improving tuberculosis disease control by eradication of persistent bacteria, the optimal dose of rifampicin that kills persistent bacteria and shortens the treatment duration is unknown.
Introduction
TB remains one of the most prevalent and lethal infectious diseases worldwide, despite the advent of anti-TB drugs and global healthcare initiatives, and leads to 2 million deaths annually. 1 Although the current drug regimen is effective, 6 months of chemotherapy is necessary to achieve a cure. The long duration of therapy leads to poor patient compliance, which gives rise to high relapse rates (7%-13%) and the emergence of drug-resistant strains. 2 Thus, shortening the duration of chemotherapy is of significant clinical benefit. Unfortunately, under the current paradigm, it takes more than 6 years to bring a new drug from bench to bedside, and more than 20 years for novel drug combinations to emerge. 3 This problem is amplified by the fact that tubercle bacilli can become dormant and persistent, and undetectable by conventional tests. The persistent bacteria are tolerant to current TB drugs and difficult to eradicate using the dose levels in the current drug regimen. 4, 5 Therefore, to bridge the gap, there is an urgent need to optimize the doses of the drugs that are already used in the standard treatment regimen to maximize their bactericidal and sterilizing activities. 6 Of the current anti-tuberculous drugs, rifampicin was introduced at suboptimal doses. 6, 7 Rifampicin exhibits bactericidal activity (killing actively growing organisms) and sterilizing activity (killing the persisting bacilli that are responsible for relapse). 6, [8] [9] [10] It can be used at higher doses without serious adverse effects. [11] [12] [13] [14] Previous studies showed that high-dose rifampicin therapy up to 35 mg/kg is well tolerated in humans [14] [15] [16] and increases the rate of tuberculosis clearance. 15 Similar observations were made in mice 13, [17] [18] [19] with a maximum tolerable daily dose of 160 mg/kg. 19 Recent results of a randomized clinical trial in South Africa and Tanzania by the PanACEA consortium suggested that rifampicin at 35 mg/kg was more efficacious than the standard rifampicin dose 21 to recommence multiplication. We demonstrated for the first time, to our knowledge, that a highdose rifampicin drug regimen was able to kill CF-dependent persistent bacteria, enabling a shortened treatment duration in mice without disease relapse. 13 However, in our previous study, we only used one high dose of the drug (50 mg/kg). It is therefore crucial to find the minimum dose size of rifampicin capable of killing persistent bacteria with a favourable toxicity profile for patients.
Herein, we studied the therapeutic effects of incremental doses of rifampicin in combination with isoniazid and pyrazinamide in the Cornell mouse model. We measured the rate of elimination of bacterial cfu counts and relapse rates. We detected and quantified persistent bacilli in cfu count-free organs using M. tuberculosis culture filtrates.
Materials and methods

Bacterial strains and growth conditions
M. tuberculosis strain H37Rv was mouse-passaged and grown in 7H9 medium supplemented with 10% albumin dextrose complex (Becton and Dickinson, UK) and containing 0.05% Tween 80 at 37 C without disturbance for 15 days. The culture was subsequently stored at #70 C for animal infection. To determine the viable counts prior to infection, cfu counting was performed prior to freezing and once again after thawing. cfu counting was carried out by plating serial 10-fold dilutions of the cultures on 7H11 agar medium supplemented with oleic albumin dextrose complex (Becton and Dickinson, UK). Colonies were counted after incubation of the plates at 37 C for 3-4 weeks and viability was expressed as log cfu/mL. The cultures were subsequently diluted in PBS and used for inoculations in mice. All culture media were made selective by the addition of 200U/mL polymyxin B, 100 mg/L carbenicillin, 20 mg/L trimethoprim and 10 mg/L amphotericin B (Selectatab, Mast Diagnostica GmbH). Human medicines of rifampicin (Rifadin capsules, Sanofi Aventis), isoniazid (isoniazid tablets, Focus) and pyrazinamide (Zinamide tablets, Genus Pharmaceuticals) were used in this study.
Cornell mouse model
Rifampicin's effectiveness at different doses in combination with isoniazid and pyrazinamide was tested using the Cornell mouse model. 22, 23 The model was conducted using the experimental design and procedure described previously. 24 Briefly, as shown in Table 1 , at 3 weeks after M. tuberculosis H37Rv infection, treatment was given to female BALB/c mice for 14 weeks with 150 mg/kg pyrazinamide plus 25 mg/kg isoniazid combined with 10, 20, 30, 40 or 50 mg/kg rifampicin by daily oral administration for 5 days per week. A sample of 4 mice was sacrificed at the beginning of the treatment and 8 mice were sacrificed in the 2nd, 4th, 6th, 8th, 11th and 14th week of treatment to monitor cfu counts. The organ homogenates from the 6th to 14th weeks were cultured in selective Kirchner liquid medium for 4 weeks with subsequent subculturing onto selective Löwenstein-Jensen slopes for a further 4 weeks.
Immediately after termination of 14 weeks of chemotherapy, the remaining mice were administered 0.5 mg/mouse of hydrocortisone acetate by daily oral administration for 8 weeks to suppress their host immunity, and cfu counts from the lungs and spleen were performed to determine disease relapse.
Ethics
Animal husbandry and all animal experiments were performed according to the Animals Scientific Procedures Act, 1986 (an Act of the Parliament of the United Kingdom 1986 c. 14) (Home Office Project licence no. 70/7077) with approval from St George's, University of London ethics committee.
Pharmacokinetics of rifampicin in BALB/c mice
Pharmacokinetic (PK) profiles of rifampicin were determined in uninfected and infected mice in a dose-ranging study with regimens matching those used in the Cornell mouse model administered orally by gavage. There were three BALB/c mice in two parallel uninfected or infected groups (total n " 12 each). The infected group had been treated previously with each of these drug regimens for 8 weeks. After both groups were given the drug regimens, serial venous blood samples (20 lL) were collected at time points 1, 2, 3, 4, 5, 6, 8 and 24 h post-dose by tail puncture and mixed with 40 lL of water. The blood samples were stored at -80 C and subsequently transported in dry ice to GlaxoSmithKline Tres Cantos for bioanalysis. The concentrations of rifampicin in the blood were determined by UPLC-MSMS assay. PK parameters were calculated using a non-compartmental analysis model in the R software package (version 3.3.2).
Resuscitation of M. tuberculosis in mouse lungs and spleens
For resuscitation of M. tuberculosis grown in mouse organs, culture filtrates containing RPF were used as described previously. 13, 21, 24 M. tuberculosis
H37Rv was grown in 7H9 medium for 15-20 days until an optical density of 1-1.5 was reached. The cultures were harvested by centrifugation at 3000 g for 15 min and sterilized by filtration with 0.2 lm filters (Sartorius) twice. The culture filtrates were made selective by addition of 200 U/mL polymyxin B, 100 mg/L carbenicillin, 20 mg/L trimethoprim and 10 mg/L amphotericin B (Selectatab, Mast Diagnostica GmbH). Broth counting of lungs and spleens was performed as serial 10-fold dilutions in triplicate in which 0.5 mL of tissue homogenates was added to 4.5 mL of the culture filtrates. At 10 day intervals over a 2 month period of incubation at 37 C, the broth cultures were examined for visible turbidity changes. The patterns of High-dose rifampicin to treat murine tuberculosis JAC positive and negative growth tubes were used to calculate the most probable number (MPN) of the bacilli. 25 Growth of M. tuberculosis in turbid tubes was confirmed by colony morphology on 7H11 agar plates. The absence of microorganisms other than mycobacteria from turbid tubes was confirmed by plating on blood agar medium (Oxoid) and Sabouraud dextrose agar (Oxoid). In order to assess the sterility of culture filtrates free of M. tuberculosis, tubes containing culture filtrates were incubated at 37 C for 2 months to ensure the absence of M. tuberculosis.
Statistical analysis
A simple model for monoexponential bacterial growth and elimination was used. 24, 26 Standard errors of parameter estimates were calculated using the method outlined by Landaw and DiStefano 27 with the Jacobian of model parameter sensitivities estimated using a numerical central difference method. The datasets comprising multiple individual subject animals were treated as a naive pool for data analysis purposes 28 rather than using the average of the data at each timepoint. The significance of differences between model parameter estimates under different therapies was examined with pairwise Z-tests incorporating a Bonferroni correction of 15 (including a comparison versus 50 mg/kg rifampicin monotherapy from previous data), 13 for which P values ,0.0033 would be considered significant. The significance of differences between the relapse rates was determined with pairwise Fisher's exact tests with a Bonferroni correction of 15, with P values ,0.0033 considered significant.
Results
Treatment with regimens containing different dose sizes of rifampicin in the Cornell mouse model
We investigated the effect of rifampicin at 10, 20, 30, 40 and 50 mg/kg in combination regimens with fixed standard doses of isoniazid and pyrazinamide on the rate of bacterial eradication and relapse in the Cornell mouse model. As shown in Table 2 and Figure 1 (a), there was a rifampicin dose-dependent increase in the rate of eradication of cfu counts in the lungs. With the rifampicin 10 and 20 mg/kg regimens, the rate of pulmonary bacterial eradication was slow, showing 99% killed at 3.5 and 2.5 weeks, respectively. Treatment with 30, 40 and 50 mg/kg rifampicin increased the rate of bacterial eradication (99% killed at 1.8, 1.6 and 1.4 weeks, respectively). Undetectable M. tuberculosis cfu counts were achieved in mouse lungs after 14 weeks of treatment for 10 mg/kg, 11 weeks for 20 mg/kg, 8 weeks for 30 and 40 mg/kg, and 6 weeks with 50 mg/kg rifampicin-containing regimens (Table 2) . A similar dose-response trend was observed in spleens except cfu countfree organs were achieved at 6 weeks for both the 40 and 50 mg/kg rifampicin regimens (Table 2 and Figure 1b) . These activities were confirmed by the estimates of the exponential rate constants (logarithmic base 10) for net bacterial elimination during treatment (k net_with_drug ) in both lung and spleen cfu (Table 3 ). The elimination rate constants become faster (i.e. greater in magnitude) with increasing dose, in a linear relationship in both lungs and spleens (Figure 1c and d) . In the cfu count-free organs, no tubercle bacilli were recovered as confirmed by negative cultures of the organ homogenates in selective Kirchner medium. No outward signs of toxicity or abnormal behaviour were observed in mice treated with any of the doses of rifampicin in the rifampicin-containing regimens.
Pharmacokinetics of rifampicin in combination with isoniazid and pyrazinamide
Rifampicin blood concentrations after administration of rifampicin-containing regimens combined with isoniazid and pyrazinamide were examined over a period of 24 h in both M. tuberculosis infected and uninfected BALB/c mice. As shown in Figure 2 , there was a linear, dose-proportional increase in the exposure of rifampicin as indicated by both maximal concentration of rifampicin (C max ) (Figure 2a ) and the overall drug exposure (AUC) (Figure 2b ) in both uninfected and infected mice. The dose linearity of the rifampicin PK in this range of doses was further supported by a plot of clearance versus dose from each regimen (Figure 2c ). Clearance (equal to dose/AUC) was shown to be approximately constant at 0.04 L/h/kg in both infected and uninfected animals at each dose level. Both AUC and C max of rifampicin were similar between infected and uninfected animals at all the doses examined (,30% difference in either measure at all doses uninfected versus infected).
Post-treatment level of persisters in the Cornell mouse model
In order to investigate the effect of different rifampicin dose regimens on the post-treatment level of persisters through RPF-induced resuscitation, lung and spleen homogenates at the weeks of treatment when cfu counts reached zero for each of the regimens were incubated with CF containing RPFs. As shown in Table 4 , after 14 weeks of treatment with the rifampicin 10 mg/kg regimen, despite cfu cultures being negative, the number of RPFdependent persisters was still high. At 11 weeks post-treatment, there were significant levels of CF-resuscitated bacilli in lungs and spleens for the rifampicin 20 mg/kg regimen, whereas reduced High-dose rifampicin to treat murine tuberculosis JAC numbers of persisters were present at 14 weeks of treatment. At 8 weeks of treatment, there were low numbers of persisters present after treatment with the 30 mg/kg rifampicin regimen, and complete persister eradication was seen at 11 weeks. There were no persistent bacteria at 8, 11 and 14 weeks with 40 mg/kg rifampicin treatment. The regimen containing 50 mg/kg rifampicin, although it failed to clear persisters at 6 weeks, showed no CF-resuscitated bacilli in lungs or spleens at 8, 11 and 14 weeks of treatment (Table 4) .
Relapse rate of treatment with the regimens containing different doses of rifampicin in the Cornell model
The organ cfu counts are shown in Table 5 . The treatment with the regimen containing 10 mg/kg rifampicin gave rise to M. tuberculosis-positive organs in 19/23 mice (86.3% relapse rate). The 20 mg/kg rifampicin regimen led to a 33% relapse rate after 14 weeks of treatment. In contrast, treatment with the regimens containing 30, 40 and 50 mg/kg rifampicin resulted in zero counts in the organs, indicating these to be relapse free (P , 0.001).
Discussion
TB drug regimens capable of eradicating persistent bacilli likely have the greatest clinical value by shortening treatment duration and reducing relapse rate. In this study, the efficacy of a rifampicin dose range in the standard drug regimen was studied and CF-dependent persisters were quantified at the timepoints when cfu count-free organs were reached in the Cornell mouse model. We intended to define whether we could utilize CF-dependent persistent M. tuberculosis as a biomarker for assessment of TB treatment outcome. The Cornell model is a reliable surrogate for efficacy in tuberculosis focused on disease relapse, developed more than 60 years ago by McCune et al. 22, 23 It has been used to assess the pharmacodynamics of TB drug regimens and to help the transition of drugs from critical preclinical evaluation to clinical application. 29 Our previous results demonstrated that RPFdependent bacilli constituted a major pool for disease relapse in the Cornell model. 13 It has been repeatedly shown that the standard rifampicin dose (10 mg/kg) regimen was unable to eliminate the undetectable persistent bacteria, leading to a high disease relapse. 8, 13, 24 With a high-dose rifampicin (50 mg/kg) regimen, treatment duration was shortened from 14 to 6 weeks and no relapse occurred. 13 This was attributed to the eradication of CFresponsive persistent bacilli from the infected organs. In this study, we showed that double the standard dose of rifampicin failed to remove CF-dependent persisters at both 11 and 14 weeks of treatment with a relapse rate of 33% (Table 5) . With a dose of 30 mg/kg, a zero cfu count was achieved at 8 weeks with a low number of CFdependent persisters and a further treatment period (up to 11 weeks) was needed to sterilize the organs (Table 4 ). The regimens with 40 and 50 mg/kg rifampicin resulted in true tubercle bacilli sterility (negativity for both cfu count and CF-resuscitable bacteria) in lungs and spleens at 8 weeks of treatment. Liu et al.
We present clear evidence that we were able to predict disease relapse by assessing CF-dependent persisters. For the first time, to our knowledge, we demonstrated that in mice a rifampicin dose of 30 mg/kg (a minimum threshold) or higher was able to eradicate persistent bacilli, leading to an approximately 21%-43% shortening of the treatment period with no disease relapse. Based on this observation, it may be argued that patients treated with .30 mg/kg rifampicin are likely to achieve cfu count-negative sputum faster with few or no persistent bacteria, leading to shortened treatment duration. It has been evidenced in humans that 35 mg/kg rifampicin was able to improve time to stable culture conversion in liquid media, 20 although treatment outcome is unknown in terms of treatment duration and relapse. Our data predict that high-dose rifampicin at 30-50 mg/kg should improve current clinical treatment by shortening the treatment duration and reducing relapse. This highly promising proof-of-principle work has pioneered a novel clinical method to identify and quantify persistent bacteria by RPF resuscitation to assess the clinical effectiveness of higherdose rifampicin in humans (A. Jindani, St George's University of London, personal communication).
In addition, we demonstrated that rifampicin in combination with isoniazid and pyrazinamide showed a linear relationship between its dose level and plasma exposure (C max and AUC) in both uninfected and infected mice. We also showed that the plasma exposures of rifampicin were similar in both infected and uninfected animals ( Figure 2 ). The drug exposures were about 2-fold higher than those in our previous and other group's reports. 13, 14, 17, 19 Importantly, the rifampicin dose linearity of plasma exposure coincided with the linear trend in cfu count elimination ( Figure 1 ). There was a clear linearity of the bacterial elimination rate constant as a measure of efficacy with increasing dose of rifampicin within the range of doses examined (Figure 1) . Similarly, the dose-dependent drug exposure of rifampicin is closely associated with the persistent bacterial elimination at the timepoints when cfu counts were negative. The linear trend in elimination rate constant was in agreement with the deduction of persister counts and relapse rate, namely faster elimination rates at higher doses concurred with lower persister counts and lower relapse rates. The same may be true in humans because, interestingly, the linearity of rifampicin plasma exposure with doses shown in this study is consistent with the linearity of rifampicin PK over the range of 10-35 mg/kg in humans. 14 It has been shown that with the standard dose of rifampicin (10 mg/kg), 90% of the drug was bound to human plasma proteins 30 and 97% was bound to mouse proteins; 19 therefore, only a very small amount of free drug was able to diffuse into tuberculous lesions. Here we showed that increasing the dose of rifampicin resulted in an accelerated dose-dependent eradication of persistent bacteria (Table 4) . When rifampicin concentration was increased to 30 mg/kg, high blood C max and AUC were achieved, leading to higher levels of biologically available rifampicin which were able to kill persistent bacteria. 13 The drug exposure and the unbound drug for the same dose size between mice and humans are different for rifampicin. In mice, AUCs and C max of rifampicin are at least 3-fold higher than those in humans. In contrast, the free fraction of the drug is almost 3-fold greater in humans than in mice. This suggests that the levels of active and free drug in mice leading to the greater efficacy shown in this study can be effectively reached in humans at the dose levels currently being studied in human clinical trials.
The implications of our mouse data for human patients must be considered with caution. The histopathology of tuberculosis differs in humans and mice. In humans, TB rarely kills the host in the course of the initial infection. Active disease is associated with a wide range of granuloma lesions, including bacteriabearing, necrotic granulomas undergoing central liquefaction and large open cavities, as well as closed granulomas with central caseum, fibrotic and calcified lesions. In contrast, in the standard Cornell model, infection is initiated by a high dose Determined by MPN of the diluted organ homogenies (n " 8) with the culture filtrates, mean MPN + SD. Broth counts were derived from onethird of the tissue homogenate and calculated to represent the MPN of the entire organ. The limit of detection was 1 MPN/organ. A dash indicates organs for which the colony count was positive and MPN counts were not performed. High-dose rifampicin to treat murine tuberculosis JAC of M. tuberculosis (10 5 cfu/mouse) and treatment is commenced 2-3 weeks after infection, when adaptive immunity is just established. There are no granuloma-like structures in the lungs.
In conclusion, the current recommended dosage of rifampicin of 10 mg/kg is insufficient to kill persistent bacilli in the Cornell mouse model. Rifampicin at 30 mg/kg in combination with isoniazid and pyrazinamide significantly shortened the treatment and prevented disease relapse by removing persistent bacteria. PK exposure of rifampicin and the observed cfu elimination rate constants were both linear in the range of rifampicin doses from 10 to 50 mg/kg in the combination therapy. Optimizing rifampicin to its maximal therapeutic efficacy with acceptable side-effect profiles will provide valuable information in human studies and could potentially revolutionize current tuberculosis chemotherapy.
